RetinAI Launches Discovery Platform for Ophthalmology and Optometry Clinics

Ikerian, the parent company of RetinAI, announced the launch of 'RetinAI Discovery for Clinics,' which features AI models designed to accelerate and enhance clinical decision workflows, teleophthalmology management, referral decisions, and patient management generating data efficiencies and enhancing decisions for clinics. There will be two product versions to address the needs of ophthalmologists and optometrists.

According to RetinAI, the vendor neutral and multi-modality platform is designed to harmonize, aggregate, and connect large datasets on a single, cloud-based repository for data. The data is then automatically analyzed with RetinAI’s CE-marked and Research Use Only (RUO) AI algorithms for accelerated and AI-biomarker-based treatment decisions. The AI models can be processed on DICOM and other formats for OCT and fundus imaging.

Both the ophthalmology and optometry versions of Discovery for Clinics have progression analytics to help track trends in outcomes and provide visualization to patients on the progression of their disease. The platform connects healthcare stakeholders and patients with 'Discovery Passport,' a feature that allows physicians to securely share with patients their data and remote questionnaires to improve patient engagement and ultimately continue the quality of care for patients both in and outside the clinic. The platform in both versions supports referral networks and the participation in clinical trials via the collection of Real-World Data (RWD), enabling clinics to generate additional service opportunities.

On top of these tools, the ophthalmology version features RUO AI models for a more detailed analysis of geographic atrophy, and the ability to look at future atrophy progression through the prediction progression model. 

To view EyewireTV's coverage of the launch, click here.